跳至主要内容
临床试验/NCT00001633
NCT00001633已完成2 期

A Phase II Feasibility Study of the Safety and Efficacy of Coronary Magnetic Resonance Angiography (CMRA) Imaging

National Heart, Lung, and Blood Institute (NHLBI)2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 1997年9月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
20
试验地点
2

研究概览

简要总结

Magnetic resonance imaging (MRI) is a diagnostic tool that creates high quality images of the human body without the use of X-ray (radiation). MRI is especially useful when studying the arteries of the heart (CMRA, coronary magnetic resonance angiography).

In this study researchers from several laboratories and hospitals will work together to determine the safety and effectiveness of CMRA with MS-325. MS-325 is a contrast agent. It is given to patients undergoing CRMA in order to improve the appearance of the arteries of the heart.

详细描述

In this multicenter trial, the safety and efficacy of magnetic resonance imaging (MRI) for visualization of the coronary arteries (CMRA, coronary magnetic resonance angiography) with MS-325. MS-325 is a new blood pool radiological contrast agent which will be assessed as part of a phase II feasibility study. The Laboratory of Cardiac Energetics in collaboration with the Department of Cardiology at the George Washington Hospital Center will be one of the six participating sites for this study.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

研究点 (2)

Loading locations...

相似试验